News & Events

Financial Results

Inventiva reports 2023 First Quarter Financial Information and provides a corporate update

Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US

28 November 2022

Inventiva announces a new Director of the Board of Directors

21 November 2022

Inventiva reports 2022 Third Quarter Financial Information

10 November 2022

Inventiva provides an update on the development of cedirogant by AbbVie

31 October 2022

Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022

21 October 2022

Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results

7 September 2022

Inventiva Reports 2022 First-Half Financial Information

Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D

Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022

Inventiva joins the Euronext Tech Leaders segment

Inventiva announces participation at several investors conferences in May and June 2022

Results of the votes of the Combined Shareholders’ Meeting of May 19, 2022

Description of the share repurchase program authorised by the Ordinary General Meeting of 19 May 2022

Inventiva secures a €50 million credit facility from the European Investment Bank

Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis

Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results

28 February 2022

Inventiva reports cash position and revenues for Full-Year 2021

14 February 2022

Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases

Inventiva to present at the 39th Annual J.P. Morgan Healthcare Conference

Inventiva announces design of Phase III clinical trial with lanifibranor in NASH

Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis

7 December 2020

Inventiva receives positive FDA feedback to advance its lead drug candidate lanifibranor into pivotal Phase III in NASH

10 November 2020

Inventiva announces the appointment of Dr. Michael Cooreman as Chief Medical Officer

5 November 2020

Inventiva announces the publication of a scientific paper on the role of PPARs in the treatment of NASH in the medical journal Nature Review Gastroenterology & Hepatology

2 November 2020

Inventiva announces the additional acceptance of two late-breaking abstracts at the AASLD The Liver Meeting Digital Experience™ 2020

2 November 2020

Inventiva to host a Key Opinion Leader webcast from the AASLD The Liver Meeting Digital Experience™ 2020

28 October 2020

Inventiva announces the pricing of its initial public offering on the Nasdaq Global Market

Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)

Inventiva files registration statement for proposed initial public offering in the United States

Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH)

Inventiva to participate at the Jefferies Virtual Healthcare Conference

Inventiva secures a new patent for lanifibranor in China expanding the protection of its lead product candidate

Inventiva secures €10.0 m non-dilutive loan facility guaranteed by the French State in the context of the COVID-19 pandemic

Inventiva’s latest research on odiparcil’s mechanism of action published in leading peer-reviewed scientific journal PLOS ONE

Q1 2020 Financial Information

Shareholders Meeting of May 28, 2020 – Availability of the preparatory documents and methods for participating and voting at the meeting

Inventiva to provide an update on the NATIVE Phase IIb clinical trial in NASH during a Key Opinion Leader webcast

Inventiva provides a corporate business update in the context of the COVID-19 pandemic

Inventiva announces completion of patient visits for its Phase IIb clinical study with lanifibranor in NASH

2019 Full-Year Results: Significant progress in NASH, MPS VI and psoriasis, and extended cash runway

Inventiva to present at the Cowen and Company 40th Annual Health Care Conference

19 February 2020

Inventiva files a prospectus in the context of the admission to trading of new shares on Euronext Paris

10 February 2020

Inventiva completes a capital increase of €15 m subscribed by existing shareholders

7 February 2020

Full-Year 2019 : Cash position and revenues

5 February 2020

Inventiva selected to present the positive results from its Phase IIa clinical study with odiparcil in MPS VI at the 16th « Annual WORLDSymposiumTM »

3 February 2020

Inventiva admitted to the SRD “Long only” on the regulated market of Euronext Paris

Inventiva announces positive results from Phase IIa clinical study with odiparcil in mucopolysaccharidosis type VI

18 December 2019

Inventiva receives a €3.5 m milestone payment from AbbVie

3 December 2019

Q3 2019 financial information and update on the partnership with Boehringer Ingelheim

13 November 2019

1 2

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
ak_bmsc	2 hours	This cookie is used by Akamai to optimize site security by distinguishing between humans and bots
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
JSESSIONID	session	The JSESSIONID cookie is used by New Relic to store a session identifier so that New Relic can monitor session counts for an application.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Cookie	Duration	Description
pll_language	1 year	The pll _language cookie is used by Polylang to remember the language selected by the user when returning to the website, and also to get the language information when not available in another way.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_173436417_1	1 Jour/s	Ces cookies sont utilisés pour collecter des informations sur la façon dont les visiteurs utilisent notre site Web. Ceci est unique au propriétaire du site Web
_gat_gtag_UA_55628332_1	1 minute	Set by Google to distinguish users.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Cookie	Duration	Description
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Cookie	Duration	Description
43410	session	No description available.
43411	session	No description
bm_mi	session	No description available.
DrupalVisitorMobile	session	No description available.
GZIP	5 years	No description available.

Q3 2019 financial information and update on the partnership with Boehringer Ingelheim